At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 144 enrolled
Drug / intervention
Andecaliximab +1 moredrug
Likely dose
Andecaliximab 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Andecaliximab and Nivolumab for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 144 participants across 34 sites in 9 countries.
Detailed Summary
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, France, Hungary, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionNov 2017
Study CompletionAug 2019
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartSep 1, 2016
Primary CompletionNov 8, 2017
Study CompletionAug 23, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.9 years ago
Interventions
Andecaliximabdrug
800 mg administered via IV infusion
Nivolumabdrug
3 mg/kg administered via IV infusion